Shanghai Shyndec Pharmaceutical News

Sinopharm Hyundai (600420): The reform of Sinopharm's unified chemical industry platform has paid off

華福證券May 12 00:00

Sinopharm Hyundai (600420): The reform of the central enterprise chemical platform integrating API formulations is expected to improve efficiency and profitability

信達證券Apr 26 00:00

Sinopharm Hyundai (600420) Incident Review Report: Quarterly Revenue Growth Resumed, Major Shareholders' Capital Increases Highlight Platform Value

華鑫證券Apr 26, 2023 00:00

Sinopharm Hyundai (600420): The blueprint for Sinopharm Group's participation in the fixed growth industry platform is beginning to appear

財通證券Apr 14, 2023 20:17

Hyundai Pharmaceuticals (600420) Incident Review: The Issuance of Convertible Bonds Favors the Company's API and Pharmaceutical Upgrades

興業證券Mar 28, 2019 00:00

Hyundai Pharmaceutical (600420) Third Quarterly Report Review: The three-quarter report's performance slightly exceeded expectations, and the company's operations are on the right track Consistency evaluation continues to advance

東興證券Oct 31, 2018 00:00

Hyundai Pharmaceutical (600420) interim report review: Performance recovery is good, and integration results are gradually showing

國聯證券Aug 21, 2018 00:00

Hyundai Pharmaceutical (600420) Interim Report Review: Performance Meets Expectations, Integration and Synergies Show

財通證券Aug 20, 2018 00:00

Hyundai Pharmaceutical (600420) Interim Report Review: Performance Meets Expectations, Operations of Various Branch Companies Are Gradually on Track, Consistency Evaluation Continues to Advance

東興證券Aug 17, 2018 00:00

Comment on the Quarterly report of Modern Pharmaceutical (600420): Q1 performance is in line with the expected preparation, the high growth of the preparation drives the higher-than-expected operation on the revenue side to gradually step into the right tr

東興證券Apr 19, 2018 00:00

Comment on Hyundai Pharmaceutical (600420) Annual report: the restructuring company failed to meet its promise to drag down the performance and continue to pay attention to consistency evaluation and API elasticity.

東興證券Mar 23, 2018 00:00

Comment on Modern Pharmaceutical (600420) event: issuing Convertible Bonds to break through the bottleneck of Development

國海證券Dec 12, 2017 00:00

Comment on Hyundai Pharmaceutical (600420) Quarterly report: the performance of rapid cost growth is slightly lower than expected.

國泰君安Oct 27, 2017 00:00

Comment on the third quarterly report of Hyundai Pharmaceutical (600420): more fees in the third quarter are the lowest point of the year, undervalued performance reversal logic remains unchanged.

東興證券Oct 26, 2017 00:00

Hyundai Pharmaceutical (600420) Quarterly Report Review: The API sector affects the medium- to long-term development of the overall performance consistency evaluation layout

東吳證券Oct 26, 2017 00:00

Hyundai Pharmaceuticals (600420) Incident Review: Azithromycin Approval Transfer Accelerates Haimen Reversing Losses

國海證券Sep 15, 2017 00:00

Hyundai Pharmaceutical (600420) Interim Report Review: Steady Growth in Performance, Steady Progress in Resource Integration

興業證券Aug 22, 2017 00:00

Hyundai Pharmaceutical (600420) Semi-Annual Report Review: Performance Growth Shows Steady Integration and Synergistic Effects

國聯證券Aug 21, 2017 00:00

Review of the semi-annual report of Hyundai Pharmaceutical (600420): Steady growth in performance and the potential for consolidation is expected to continue to be explored

國泰君安Aug 21, 2017 00:00

Hyundai Pharmaceutical (600420) Interim Report Review: Performance Meets Expectations, Flexible Space in Multiple Sectors

民生證券Aug 21, 2017 00:00